Description of possible side effects of Teritusumab/Telicot

Teritusumab (Teclistamab-cqyv) is an immunotherapy drug that works by activatingT cells. Its adverse reactions are mainly related to immune system activation. Understanding potential side effects and conducting standardized monitoring are important links in ensuring treatment safety. In the early stages of treatment for multiple myeloma(MM), the more common adverse reactions are related to immune responses.

1. Fever, chills or flu-like symptoms

2. Fatigue, loss of appetite or general discomfort

3. Redness, swelling, pain or itching at the injection site

Some patients may experience cytokine release-related reactions during the escalating dose phase, usually manifesting as fever, hypotension, or heart rate changes. Therefore, this phase usually requires hospitalization for observation for timely treatment.

In terms of blood system, teritolumab may affect bone marrow hematopoietic function.

1. Decreased white blood cells or neutrophils

2. Fluctuations in platelet levels

3. Exacerbation of anemia-related symptoms

Therefore, blood routine monitoring needs to be regularly monitored during treatment, and symptomatic and supportive treatment should be provided if necessary.

The risk of infection is also a major concern when using this drug. As the immune system is reregulated, some patients may have a temporarily reduced defense against bacterial or viral infections. Clinically, infection screening and preventive management are often strengthened to reduce risk.

In addition, a small number of patients may experience neurological-related symptoms, such as headache, confusion, or decreased concentration. This type of reaction usually needs to be differentiated from other causes, and a doctor's assessment is required to decide whether to adjust the pace of treatment.

Overall, the adverse reactions of teritusumab are predictable and most can be controlled through standardized monitoring and timely intervention. Under the management of a professional medical team, its safety has been gradually verified in clinical practice. Patients fully understand the risks before treatment, which helps improve compliance and overall treatment experience.

Keyword tag: Teritusumab Side Effects Telica Adverse ReactionsImmunotherapy Multiple myeloma Drug safety

Reference materials:https://www.ema.europa.eu/en/documents/product-information/tecvayli-epar-product-information_en.pdf